Lexi Ventures

Lexi Ventures invests in early stage gene tech companies. This focus is rooted in these beliefs. 1. Genetic engineering will change the lives of all people to a degree comparable with electricity, the internet, and artificial intelligence. 2. This will enable startups to create unmatched opportunities for wealth creation for their customers, employees, and investors. 3. The convergence of protein modeling, harnessing CRISPR, falling costs, and growing talent has made this the right time for the thesis. 4. There is more alpha in gene tech than other bio, health, and deep tech businesses. Gene tech startups aim to cure many of the worst and most expensive diseases, improving happiness and reducing healthcare needs. Other gene tech startups will enable plants and microbes to produce newer and better things while sustaining the natural environment.

Lexi Ventures is proud to back TippingPoint Biosciences in their development of therapies for #cancers implicating chromatin packing.

How do you set valuation of your early stage Biotech company ? Great question and most biotech founders struggle with this. Often times VCs and partners will ask you what you think your company is valuation is during early stages. How do you come up with this? After all, they have the models and comps and will likely set terms regardless. If you're a single asset company, an NPV or similar model could work. But you have to predict drug prices and take into account market up take rates and payers/ insurance and all sorts of factors. Can be really hard for an early founder or CEO. If you're a commercial life science or biotech product, service or software, should be easier to do an NPV or look at IRR and get a pretty good idea. Again can feel like a big task and challenge to come up with a valuation others will agree with. Hardest may be the platform. Probably only way to set this is using comps but that can be so difficult with the variation in the type of platforms that exist. Also, the market has shifted so dramatically over the past couple of years and valuations have dropped, so picking the right comps can be a hurdle. Either way, this is challenging and it can feel overwhelming knowing the valuation of your company you set can dictate the future and overall direction. Talk to as many people as you can! Be confident in your valuation by knowing your value of your product(s) but be willing to take advice and adjust. #EarlyStageCompany #VentureCreation #Biotech #Biopharma #DrugDiscovery #Therapeutics #LifeScience #Valuations #NPV #DCF #FinancialModeling

Lexi Ventures is proud to back QUiCKR Bio.

Portco #proteomics role

Portco #signalprocessing role #DSP #software

This is one of my standard written requests to gene tech entrepreneurs raising money. "Describe your product in 5 to 20 words that cover the one or two most important differences it has from other products. Do not describe the problem it solves, its benefits, or how great it is." Roughly 2 out of 3 succeed.

A possible opportunity for biotech founders who are fundraising.

Thought of the day... A diagnostic test that always shows a positive result will be correct for 100% of positive cases. But it’s completely useless. #diagnostics

Oil made Saudi Aramco. Computers made Microsoft. The internet made Google. Mobile made Apple. AI made Nvidia. Gene tech will make the next $1T company that nobody has heard of yet. Lexi Ventures aims to fund it at seed stage. #LexiVentures #genetech